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Over a century ago, Ehrlich realized that ani-
mals must avoid “horror autotoxicus” and pre-
vent immune attack on self-tissues. This is 
accomplished, in part, by deletion of highly self-
reactive clones. The current T cell development 
paradigm reasons that thymocytes recognizing 
self-peptide–MHC complexes with high affinity 
are programmed to die. Yet, T cells are posi-
tively selected because of their ability to recog-
nize a diverse set of self-peptides bound to MHC 
complexes (1, 2) and weak-to-moderate affinity 
self-reactive T cells do escape negative selection 
(3). Some of these CD8+ and CD4+ T cells are 
capable  of  recognizing  self-antigens  expressed 
by tumors, including cancer-testes antigens, and 
differentiation antigens (4). Melanosomal mem-
brane glycoproteins are a well-characterized 
family of differentiation antigens that are recog-
nized by low-frequency CD8+ T cells of mela-
noma  patients  (5).  In  the  mouse,  this  family 
includes gp100/pmel-17, a type I melanosomal 
membrane protein involved in the polymeriza-
tion of melanin (6).
To  generate  a  robust  immune  response 
against a self-protein, mechanisms of tolerance 
must  be  circumvented.  Vaccination  with  al-
tered forms of the antigen is an effective, widely 
studied method of overcoming peripheral tol-
erance (7–9). We have reported preclinical and 
clinical use of a plasmid delivery system that 
utilizes high pressure to drive cutaneous particle 
bombardment of DNA, leading to presentation 
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A primary goal of cancer immunotherapy is to improve the naturally occurring, but weak, 
immune response to tumors. Ineffective responses to cancer vaccines may be caused, in 
part, by low numbers of self-reactive lymphocytes surviving negative selection. Here, we 
estimated the frequency of CD8+ T cells recognizing a self-antigen to be <0.0001% (1 in 
1 million CD8+ T cells), which is so low as to preclude a strong immune response in some 
mice. Supplementing this repertoire with naive antigen-specific cells increased vaccine-
elicited tumor immunity and autoimmunity, but a threshold was reached whereby the 
transfer of increased numbers of antigen-specific cells impaired functional benefit, most 
likely because of intraclonal competition in the irradiated host. We show that cells primed 
at precursor frequencies below this competitive threshold proliferate more, acquire poly-
functionality, and eradicate tumors more effectively. This work demonstrates the functional 
relevance of CD8+ T cell precursor frequency to tumor immunity and autoimmunity. Trans-
ferring optimized numbers of naive tumor-specific T cells, followed by in vivo activation, is 
a new approach that can be applied to human cancer immunotherapy. Further, precursor 
frequency as an isolated variable can be exploited to augment efficacy of clinical vaccine 
strategies designed to activate any antigen-specific CD8+ T cells.
© 2009 Rizzuto et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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pothesized  that  the  strength  of  the  antitumor  immune 
response was in part determined by the size of the tumor-
specific precursor pool. Therefore, we sought to determine 
the endogenous frequency of CD8+ T cells specific for a self-
antigen, and to characterize the antitumor immune response 
generated from different T cell precursor frequencies.
Here, we present our studies combining vaccination with 
adoptively transferred, naive, gp100-specific CD8+ T cells 
activated in vivo. We estimate the frequency of endogenous 
CD8+  cells  recognizing  gp10025-33  to  be  extremely  low, 
<0.0001% of CD8+ T cells, an implication of which is that 
some genetically identical animals do not mount strong, pro-
tective responses to vaccination. We demonstrate that sup-
plementing the naive repertoire with gp10025-33-specific cells 
increases vaccine-elicited tumor immunity. However, at very 
high input numbers, this benefit is negated because of intra-
clonal competition. These data show that CD8+ T cell pre-
cursor frequency has a striking effect on clinically relevant 
disease. Our results demonstrate that precursor frequency can 
be manipulated to advantage, and must at least be considered 
in therapeutic strategies of adoptive immunotherapy.
RESULTS
Determination of self-antigen–specific CD8+ T cell 
precursor frequency
We have previously shown that repeated vaccination of naive 
wild-type mice with plasmid DNA encoding mutated mela-
noma antigens elicits a low-frequency CD8+ T cell response 
(<1% IFN-+ of CD8+) (8). We found that a preconditioning 
regimen of sublethal irradiation (600 cGy) and adoptive transfer 
of 30 million naive splenocytes 1 d before the first vaccination 
increases the CD8+ T cell response and enhances protection 
from subsequent challenge with tumor (unpublished data). This 
treatment strategy generates responses that are readily detectable 
by flow cytometry, and because it is a clinically relevant model, 
it was chosen for use in the experiments presented here.
As central and peripheral tolerance mechanisms might be 
expected to leave animals with few functional precursors spe-
cific for self-antigens, we wanted to determine the exact pre-
immune frequency for CD8+ T cells recognizing a melanoma 
antigen and evaluate how this impacted our melanoma treat-
ment strategy.
To indirectly assess this number within the preimmune, 
naive CD8+ population, we adopted a method first described 
by Blattman et al. (23) and used the pmel-1 TCR transgenic 
mouse (30). Pmel-1 mice express a V1V13 gp10025-33-reac-
tive TCR transgene, and thus served as a source of transplant-
able CD8+ tumor-antigen–specific cells used to estimate 
precursor frequency for the gp100 self-antigen. It was reasoned 
that an antigen-induced effector response would be equally 
composed of endogenous and transgenic cells when they were 
present at similar initial precursor frequencies (23, 26). As vali-
dation of this approach using our tumor therapy model of   
irradiation and adoptive transfer, we performed a titration   
experiment with OT1 CD8+ T cells. Mice were treated with 
600 cGy irradiation, followed by adoptive transfer of different 
of antigen by dendritic cells in skin draining LNs (DLNs) (10, 
11). Active immunization of mice with plasmid encoding hu-
man gp100 (hgp100) generates a response composed of CD8+ 
T cells that cross-react with an immunodominant epitope 
(amino  acids  25–33)  from  the  wild-type  self-protein  pre-
sented by H-2Db (10, 12). Although this strategy allows for 
the generation of low-level, detectable responses, the growth 
of established tumors is barely impeded. Indeed, active vacci-
nation strategies alone, although considered safe, have yielded 
poor responses in clinical trials (13).
Recent work has shown that delivering antitumor vac-
cines while cells are undergoing lymphopenia-induced ho-
meostatic expansion enhances CD8+ T cell responses (14, 15). 
This augmentation is caused by the availability of homeostatic 
cytokines, removal of regulatory populations, increased self-
peptide–MHC reactivity of homeostatically proliferating cells, 
and irradiation-induced release of danger signals (16–18). We 
designed a strategy to induce more potent tumor immunity 
that combines sublethal irradiation, adoptive transfer of naive 
splenocytes, and vaccination against gp100. This treatment is 
moderately  effective  at  preventing  melanoma  growth  in  a 
prophylactic setting, but is much less potent when adminis-
tered to a tumor-bearing mouse (unpublished data). Fortu-
nately,  the  literature  suggests  many  ways  to  improve  this 
treatment, including but not limited to, addition of adjuvants, 
multi-epitope vaccination, and targeted removal of suppressor 
populations. Here, we chose to focus on a previously unex-
plored parameter: the frequency of self-antigen–specific CD8+ 
T cells present at the time of in vivo priming.
How many of the 20 million naive CD8+ T cells in a 
mouse are specific for a particular epitope? The theoretical di-
versity of TCRs on mature T cells has been estimated at 1013 
possibilities (19), but this may be an overestimate if documented 
constraints and biases on the generation of functional TCRs are 
considered. The study of individual clonotypes in the preim-
mune repertoire is made difficult because it requires the detec-
tion of small numbers of cells among millions. Nevertheless, 
immunologists have used indirect and direct methods to assess 
the preimmune repertoire for several well-studied foreign epi-
topes. Estimates range from 10 to 3,000 antigen-specific cells/
antigen/mouse (20–26). To date, the lowest reported estimates 
for epitope-specific frequency is 16 CD4+ cells recognizing 
OVA and the highest is 3,000 CD8+ T cells that recognize 
gp33 from LCMV (21, 24).
Two recent reports demonstrate that natural differences 
in the size of three CD4+ (21) and six CD8+ foreign antigen–
specific T cell populations (22) are important determinants of 
the magnitude of the effector and memory response. Further, 
it has been suggested that low CD8+ T cell precursor fre-
quency may partially account for patterns of immunodomi-
nance and explain why certain well-processed and presented 
foreign epitopes fail to elicit strong immune responses in the 
context of infection (27, 28). Mechanisms of central and pe-
ripheral deletion might be expected to leave the mouse with 
even fewer precursors specific for self-antigens (29), thus lim-
iting the generation of robust antitumor responses. We hy-JEM VOL. 206, April 13, 2009 
ARTICLE
851
Figure 1.  The precursor frequency of CD8+ T cells recognizing gp10025-33 in the naive repertoire is estimated to be ~1 in 1 million CD8+ T cells; 
vaccination induces an oligoclonal, private response. (A and B) Sublethally irradiated animals received adoptive transfer with 30 million splenocytes contain-
ing titrating doses (0, 101, 102, and 103) of pmel-1 CD8+Thy1.1+ cells. Three weekly vaccinations with hgp100-encoding plasmid began the following day, and DLNs 
were harvested 5 d after the last vaccination. Cells were stained and analyzed by flow cytometry to determine frequency and absolute number of hgp100-tetra-
mer+ cells, as well as the relative contributions of Thy1.1+ (transgenic) cells and Thy1.2+ (endogenous) to this response. In A, representative contour plots are 
shown for mice in each pmel-1 dose group. (B) Mean absolute number of CD8+tetramer+ cells in DLN (n = 3 mice/group; error bars represent the SD). (C) Larger 
cohorts (n = 10 mice/group) were prepared as in A, with animals receiving either 0 or 101 initial pmel-1 cells. The absolute number of Thy1.1+ (transgenic) or 
Thy1.2+ (endogenous) CD8+tetramer+ cells in DLNs of those animals that responded above background to vaccine is shown. Flow cytometric contour plots are 
displayed as supplemental data (Fig. S1). (D) Spleens and DLNs of responders were stained for TCR V gene segment expression. Usage profiles for individual mice, 
as well as for CD8+ cells from a naive nonvaccinated control, are shown as pie graphs. Roman numerals indicate samples that were subjected to cloning of TCR 
V CDR3 regions, as reported in Table I. Data shown in A–C are representative of at least three experiments performed under similar conditions. D is representa-
tive of nine individual mice from two independent experiments.  Fig. S1 is available at http://www.jem.org/cgi/content/full/jem.20081382/DC1.852 T CELL PRECURSOR FREQUENCY AND TUMOR IMMUNITY | Rizzuto et al.
frequencies of OT1 CD8+ T cells mixed with naive spleno-
cytes. Because all mice receive the same total number of 30 
million cells, the only variable is the frequency of transgenic 
cells. Vaccination with plasmid encoding SIINFEKL estimated 
OT1-specific precursor frequency to be between 10 and 100 
cells (unpublished data). This is consistent with literature esti-
mating the number of foreign antigen–specific CD8+ cells 
within the naive repertoire (23, 31).
To measure gp10025-33-specific endogenous precursor fre-
quency, mice were sublethally irradiated and adoptively trans-
ferred with 30 million splenocytes that included 0, 101, 102, or 
103 pmel-1 cells (Fig. 1). Starting the following day, animals 
were vaccinated weekly for 3 wk with plasmid encoding hgp100. 
5 d after the last vaccination, individual spleens and DLNs were 
harvested, and the relative contributions of transgenic (Thy1.1+) 
and endogenous (Thy1.2+) cells to the gp100-tetramer+ popula-
tion was assessed (Fig. 1, A–C). The endogenous response was 
barely detectable in animals receiving 103 pmel-1 cells. This is 
most likely because 103 transgenic cells outcompete endogenous 
clones, suggesting an endogenous precursor frequency of <0.02%. 
The endogenous response was also largely eliminated when 102 
pmel-1 cells were transferred (Fig. 1, A and B). However, mice 
receiving 101 pmel-1 cells generated a response that included 
endogenous cells (Fig. 1, A–C). Preparation of larger cohorts 
demonstrated that of 10 mice that received 0 pmel-1 cells,   
2–3/10 mice had no detectable response above background 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20081382/DC1). One explanation for this is that these ani-
mals did not possess a TCR capable of recognizing this self-anti-
gen at the time of vaccination. Finally, we comparatively assessed 
the affinity of endogenous and pmel-1 responders in individual 
mice. The frequency of IFN-+ endogenous and/or pmel-1 
cells were measured for titrating amounts of mouse gp10025-33 
peptide, and response curves were generated (unpublished data). 
When compared with pmel-1 cells, half-maximal recognition of 
mgp10025-33 occurred at higher concentrations of peptide for 
endogenous responding cells. This suggests that these endoge-
nous responders were of lower avidity than pmel-1 cells.
In this irradiation and adoptive transfer model, mice possessed 
5 × 106 CD8+ T cells at the time of first vaccination, there-
fore yielding a calculated precursor frequency of 1 gp10025-33  –
specific cell per 1.0 × 106 CD8+ T cells. This is approximately 
an order of magnitude lower than has been reported for CD8+ 
T cells recognizing foreign antigens (22, 23, 31). Indeed, a pre-
cursor frequency of 5 gp10025-33–specific cells/mouse would 
suggest that small numbers of clones are represented in the 
effector population. To directly test whether the endogenous 
hgp100-tetramer+ population was oligoclonal, we stained cells 
from individual responders with antibodies recognizing TCR 
V families. As shown in Fig. 1 D, each of nine individual 
responses tested was composed of between one and four V 
families, with no evidence of a preferred V. To address the 
number of clones present within each responding V family, 
hgp100-tetramer+ cells were FACS sorted, and TCR V 
CDR3 regions were PCR amplified, cloned, and sequenced. 
Remarkably, nearly all of the individual V families contained 
only one or two CDR3 regions (Table I).
These results reveal that the CD8+ T cell response to the self-
epitope gp10025-33 is oligoclonal and private. The data suggest 
that in some genetically identical animals, the gp10025-33–specific 
precursor frequency may reach “functional” zero. A similar low 
frequency of tumor-specific cells in cancer patients may contrib-
ute to poor responses to cancer vaccines targeting self-antigens, 
and provides rationale for supplementing the naive repertoire 
with increased numbers of antigen-specific CD8+ T cells.
Initial self-antigen–specific CD8+ precursor  
frequency dictates tumor immunity and autoimmunity  
in a therapeutic model
We sought to assess the role of tumor-specific CD8+ cell 
precursor frequency in rejection of intradermal melanoma 
tumors and hypothesized that treatment efficacy would be 
Table I.  Summary of endogenous TCR V and TCR J segment usage and CDR3 sequences
Mouse Percent positive for 
V by flow cytometry
CDR3-IMGT TRBV gene TRBJ gene Number of 
identical 
clones
GenBank 
accession no.
i 80% V4 A S S Q S R Y E Q Y 2*01 2-7*01 18/19a EU647570
9% V10b A S S S S G F T E V F 4*01 1-1*01 or 02 14/15b EU647566
ii 51% V13 A S S F T Q T N T E V F 14*01 1-1*01 13/13 EU647568
11% V10b A S S S T G Y Y A E Q F 4*01 2-1*01 18/18 EU647569
iii 91% V8.3 A S R D G S Y N S P L Y 13-1*01 or 02 1-6*01 32/32 EU647565
iv 34% V3 A S S L S T G Y Y A E Q F 26*01 or 02 2-1*01 20/20 EU647574
v 65% V8.3 A S S E P T G G V Y E Q Y 13-1*01 or 02 2-7*01 17/17 EU647575
9.5% V10b A S S S G G G Y A E Q F 4*01 2-1*01 11/11 EU647577
vi 100% V8.1/8.2 A S G D A W A G S Y E Q Y 13-2*01 or 03, or 04 2-7*01 19/20c EU647573
vii 70% V12 A S S L A D R G Q D T Q Y 15*01 2-5*01 19/19 EU647576
aFor 1/19 clones CDR3-IMGT is A S N Q S R Y E Q Y (accession no. EU647571).
bFor 1/15 clones CDR3-IMGT is A S I R G T E V F (accession no. EU647567).
cFor 1/20 clones CDR3-IMGT is A S G D P W A G S Y E Q Y (accession no. EU647572).JEM VOL. 206, April 13, 2009 
ARTICLE
853
splenocytes. This treatment model ensures that all mice re-
ceive the same total number of 30 million transferred cells; 
the variable is the frequency of pmel-1 cells. Dose groups 
ranged from physiological frequencies of <0.02% to supra-
physiological levels orders of a magnitude higher (Fig. 2 A). 
improved by supplementing the low-frequency gp10025-33-
specific repertoire with naive pmel-1 cells. As depicted in 
Fig. 2 A, mice bearing day 4 cutaneous B16 melanoma tu-
mors were treated with 600 cGy, followed by adoptive trans-
fer of different frequencies of pmel-1 cells mixed with naive 
Figure 2.  Tumor growth and autoimmune depigmentation elicited by adoptive transfer and vaccination is inversely correlated with CD8+ 
cell precursor frequency. (A) Experimental scheme. Thy1.2+ mice (15–16 mice/group) were intradermally inoculated with B16 cells and either left un-
treated (naive) or began treatment on day 4 consisting of sublethal irradiation and adoptive transfer of donor cells. Each experimental group received 
adoptive transfer of 30 million Thy1.1+ splenocytes, containing varying numbers of purified CD8+Thy1.1+ pmel-1 cells. All treated mice received three 
weekly vaccinations with hgp100-encoding plasmid, beginning on day 5. Animals were monitored every 3–5 d for tumor growth. (B) Incidence of pro-
gressively growing B16 tumors. (C) Tumor growth curves for individual mice. (D) At day 104 after tumor challenge, surviving mice were anaesthetized and 
imaged using a flatbed scanner. Representative ventral images from 1 animal/group are shown. Depigmentation was quantified, and mean pixel number 
and SEM is plotted in E. For groups receiving 103, 105, 106, and 6 × 106 pmel-1 cells, P < 0.001 for an overall association between the number of pixels and 
the initial pmel-1 dose. Pairwise comparisons for differences yield P < 0.001 for 103 versus 106 and P < 0.01 for 103 versus 6 × 106. Data are representa-
tive of two experiments.854 T CELL PRECURSOR FREQUENCY AND TUMOR IMMUNITY | Rizzuto et al.
mixed in Matrigel, which is a commercially available extra-
cellular matrix. This allowed for subsequent tumor removal 
at early days after treatment, and isolation and flow cytomet-
ric analysis of tumor infiltrating lymphocytes. On day 4 after 
tumor  injection,  mice  underwent  treatment  consisting  of 
sublethal irradiation, adoptive transfer with different pmel-1 
cell precursor frequencies, and vaccination (Fig. 3 A).
At days 3, 6, 8, and 13 after irradiation and adoptive transfer, 
tumor, spleen and DLN were harvested and processed to deter-
mine cell number and frequency of pmel-1 cells by flow cytome-
try. Fold expansion was calculated by dividing Thy1.1+ pmel-1 
frequency in the CD8+ population at each time point by initial 
pmel-1 frequency in the adoptively transferred CD8+ population. 
The data for mean fold expansion (Fig. 3 B) reveals that during 
this first week, pmel-1 cells present at 0.02% initial precursor fre-
quency underwent a remarkable 50–450-fold expansion. Over 
this same time period, pmel-1 cells present at 2% initial precursor 
frequency expanded approximately fivefold, whereas cells in the 
two higher dose groups barely maintained their input numbers.   
A similar trend was observed 5 d after the second vaccination 
(Fig. 3 B, Day 12), with marked increases in the fold expansion 
of the pmel-1 population notable only in the low-dose groups. 
Consistently,  expression  of  the  proliferation  marker  Ki67  in 
pmel-1 cells 5 d after the second vaccination was lower on cells 
primed at higher precursor frequencies (Fig. 3 C).
Thus, fewer pmel-1 cells transferred into a lymphopenic 
host resulted in greater expansion of the pmel-1 population 
in response to vaccine. The fact that this level of expansion is 
not observed in unvaccinated recipients (not depicted), sug-
gests that detection of self-gp10025-33 present in melanocytic 
tissue is not sufficient to drive robust expansion of pmel-1 
cells. This is presumably caused by the reported lower affinity 
of these cells for the mouse epitope, such that it is incapable 
of priming a full proliferative response (30, 33).
At higher precursor frequencies, intraclonal competition 
impairs proliferation and acquisition of an activated 
effector phenotype
To test if the impaired expansion of pmel-1 cells at the higher 
doses is caused by intraclonal competition, we measured the 
proliferation of 105 pmel-1 cells in the presence of competing 
Beginning the following day, these mice were vaccinated 
weekly for 3 wk with plasmid-encoding hgp100.
In this model, tumors in untreated animals become palpable 
at 7 d (Fig. 2 C). Notably, lower initial pmel-1 precursor fre-
quencies (0.02% and 2%) resulted in enhanced tumor rejection 
of these early progressing tumors. A delay in tumor progression 
was noticed at all pmel-1 doses, but tumor-free survival was 
most significantly enhanced at the 103 and 105 pmel-1 doses 
(Fig. 2, B and C). Adding no pmel-1 cells to the adoptive trans-
fer is of similar efficacy to the 6 × 106 pmel-1 dose (Fig. 2 and 
Table II). The overall frequency of mice without tumors at ex-
perimental endpoints, and the statistical significance for two 
experiments, is reported in Table II.
Effective generation of immunity to B16 by vaccination 
with mutated self-antigen often results in autoimmunity (9).   
Although vaccination of naive wild-type mice with hgp100 is 
not a particularly strong inducer of autoimmune coat depigmen-
tation, our treatment regimen did result in overt depigmenta-
tion, particularly in the low pmel-1 dose groups. Depigmentation 
was inversely correlated with pmel-1 dose for animals receiving 
pmel-1 cells. At day 104 after tumor challenge, coat depigmen-
tation was quantified for surviving mice (Fig. 2 E). Representa-
tives from each group are shown in Fig. 2 D.
These results identify vaccine-specific CD8+ precursor fre-
quency as a remarkably significant predictor of treatment and 
side-effect outcome. Paradoxically, above a certain threshold 
there is an inverse relationship between pmel-1 clonal frequency 
and vaccine-induced tumor rejection and autoimmune depig-
mentation. In contrast, studies using the transfer of in vitro–ac-
tivated, tumor-specific cells have demonstrated that transfer of 
greater cell numbers is generally more effective (32). Therefore, 
we considered that at high precursory frequency, the in vivo 
activation of naive pmel-1 cells was compromised.
Increased fold expansion of pmel-1 cells is observed  
at lower precursor frequencies
We characterized the antitumor immune response generated 
from the different pmel-1 precursor frequencies. We began 
by measuring the expansion of pmel-1 cells that is expected 
to occur several days after initial antigen encounter. Mice 
were subcutaneously inoculated with B16 melanoma cells 
Table II.  Summary of percentage tumor-free mice at endpoint of experiment described in Fig. 2
Treatment group Tumor-free /total mice 
replicate 1
Tumor-free /total mice 
replicate 2
Combined percent 
tumor free
Statistical significance
versus 
6 × 106
versus 
0
versus 
naive
103 11 / 14 12 / 16 77% P < 0.01 P < 0.001a P < 0.001a
105 11 / 15 14 / 16 81% P < 0.01 P < 0.001a P < 0.001a
106 10 / 15 9 / 16 52% P < 0.05 P < 0.001a
6 × 106 5 / 12 5 / 15 37%
0 (no pmel) 6 / 14 2 / 15 28%
Naive 1 / 10 3 / 15 16%
Endpoint was day 104 (replicate 1) and day 131 (replicate 2) post-tumor challenge. Statistical significance was calculated for combined experiment.
aIndicates values remaining significant after correction for multiple comparisons.JEM VOL. 206, April 13, 2009 
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The extent of proliferation of Thy1.1+ pmel-1 cells located 
in DLNs is shown in Fig. 4 B, and individual mouse variation 
is reported in Fig. 4 C. Thy1.1+ pmel-1 cells in nonvaccinated 
controls underwent several rounds of proliferation, as is ex-
pected for CD8+ T cells transferred into irradiated hosts (34). 
Vaccine greatly enhanced this proliferative burst, whereas ad-
dition of 0.9 × 106 pmel-1 competitors partially reversed this 
effect. Addition of 5.9 × 106 pmel-1 competitors more dra-
matically inhibited proliferation of the Thy1.1+ pmel-1 cells. 
However, when 5.9 × 106 OT1 competitors were cotrans-
ferred, proliferation and activation of Thy1.1+ pmel-1 cells was 
pmel-1 cells (Fig. 4 A). Sublethally irradiated recipients re-
ceived adoptive transfer of naive splenocytes that included 
105 CFSE-labeled pmel-1 cells. Co-transfer of unlabeled, 
double-positive Thy1.1+Thy1.2+ pmel-1 cells allowed for 
flow  cytometric  distinction  of  competitors  from  exten-
sively proliferated Thy1.1+ pmel-1 cells. We also included 
recipient  animals  that  received  competitor  CD8+  OT1 
cells. This served to test if the moderately increased num-
ber of total CD8+ cells transferred at the 6 × 106 pmel-1 
dose was impairing proliferation irrespective of peptide-
MHC specificity.
Figure 3.  Higher pmel-1 fold expansion at lower initial precursor frequency. (A) Experimental scheme. Thy1.2+ mice were challenged with a su-
pra-lethal dose of B16-matrigel 4 d before treatment. Animals were treated with sublethal irradiation and adoptive transfer of 30 million Thy1.2+ spleno-
cytes, with groups (n = 6 mice/group) receiving different precursor frequencies of CD8+Thy1.1+ pmel-1 cells. One day later all were vaccinated with 
hgp100-encoding plasmid. (B) At time points shown, tumor, spleen, and DLN from two mice per group were harvested, and the frequency of pmel-1 CD8+ 
cells was determined by flow cytometry. Fold expansion was calculated by dividing Thy1.1+ pmel-1 frequency among all CD8+ at each time point by initial 
frequency. The mean of two individual mice is shown. Representative of three individual experiments performed under similar conditions. (C) In separate 
experiments, nontumor-bearing animals were treated as described above with pmel-1 doses of 103, 105, 106, or 6 × 106 cells, vaccinated 1 d after adoptive 
transfer and 1 wk later. 5 d after the second vaccination, DLNs were harvested and stained for intracellular expression of Ki67. Flow cytometric overlaid 
histograms of Ki67 and isotype control (shaded) staining for the different pmel-1 dose groups are shown. Representative plots of nongp100-specific, 
CD8+ cells (CD8+Thy1.1) in the lymphopenic host, as well as naive CD8+ cells are shown. Similar pattern of Ki67 reactivity observed in three individual 
experiments.856 T CELL PRECURSOR FREQUENCY AND TUMOR IMMUNITY | Rizzuto et al.
however, was not as dramatic as was observed in the presence 
of vaccine-delivered antigen.
Pmel-1 cells that had productively encountered antigen 
would be expected to acquire an activated phenotype. There-
fore, we looked at the activation state of the Thy1.1+ pmel-1 
cells. Addition of pmel-1, but not OT1, competitors resulted 
in lower frequencies of cells that up-regulated CD44 and 
down-regulated CD62L, which is consistent with an effector 
phenotype (CD44hiCD62Llo; Fig. 4, B and D, and not de-
picted). In related experiments, we tested the acquisition of 
not affected (Fig. 4, B and C). This suggests that competition 
for hgp10025-33–peptide–MHC complexes is occurring, and 
not as obviously for a non–TCR-specific signal, such as access 
to APCs or space in the DLNs. We considered that pmel-1 
cells might also compete for endogenous peptide–MHC com-
plexes, driving homeostatic expansion for that TCR clone. 
Therefore, we assessed homeostatic proliferation of pmel-1 
cells in the lymphopenic host in the absence of vaccination. 
Higher pmel-1 cell doses resulted in slightly less vigorous   
homeostatic proliferation (unpublished data). The inhibition, 
Figure 4.  At higher precursor frequency, intraclonal competition limits the initial proliferative burst and acquisition of effector pheno-
type. (A) Experimental scheme. Mice (n = 3–5/group) underwent sublethal irradiation and adoptive transfer of splenocytes that included 105 CFSE-
labeled CD8+Thy1.1+ pmel-1 cells. Some groups received competing CD8+Thy1.1+Thy1.2+ pmel-1 cells (0.9 × 106 or 5.9 × 106) or competing 
CD8+Thy1.2+ OT1 cells (5.9 × 106). 1 d later, mice were vaccinated with hgp100-encoding plasmid, except for a control group that received no vaccina-
tion. Vaccine DLNs were harvested from individual mice 5 d after vaccination and proliferation and phenotype of CFSE-labeled CD8+Thy1.1+ pmel-1 
cells was assessed. (B) Combined flow cytometric plots of DLNs, gated on CD8+Thy1.1+ pmel-1 cells are shown. Proliferation and phenotypic data for 
DLNs of individual animals is shown graphically in C and D, respectively. Horizontal line represents mean. P = 0.03 for comparison of vaccinated ani-
mals receiving no competitors versus vaccinated animals receiving either high- or low-dose pmel-1 competitors. Representative of two experiments 
performed under similar conditions.JEM VOL. 206, April 13, 2009 
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levels of LFA-1 may not only be important in maintenance 
of the immunological synapse but may also aid in adhesion 
of pmel-1 cells at the tumor site (35). Similar trends were 
seen in the spleen (Fig. 5, B and C) and DLNs (Fig. 5 A). 
Notably, we have observed a similar inverse correlation be-
tween precursor frequency and postvaccination frequency 
effector phenotype on the pmel-1 population in mice that 
had received four different precursor frequencies (Fig. 5). 
Results consistently demonstrated an inverse correlation 
between  pmel-1  precursor  frequency  and  frequency  of 
CD44hiCD62LloLFA-1hi pmel-1 effectors. This is a pheno-
type that is typical of antigen-experienced cells, and high 
Figure 5.  Initial precursor frequency dictates acquisition of vaccine-induced effector phenotype on tumor antigen-specific CD8+ T cells.  
(A) Mice (n = 3/group) were inoculated subcutaneously with B16-matrigel tumors, underwent sublethal irradiation and adoptive transfer 4 d later, and 
vaccination with hgp100-encoding plasmid the following day. 5 d after vaccination, DLNs and spleens were harvested. Expression of CD44, CD62L, and 
LFA-1 are shown by flow cytometric contour and histogram plots of pooled DLNs (n = 3 mice/group), and are gated on CD8+Thy1.1+ pmel-1 cells. Repre-
sentative of three experiments. (B) Data shown are from spleens of individual mice in three pooled experiments. P < 0.001 for an overall inverse associa-
tion between the percentage of CD44hiCD62Llo of pmel-1 cells and initial pmel-1 dose. (C) Data shown are from individual spleens of one representative 
experiment out of three experiments. P = 0.024 for an overall inverse association between MFI of LFA-1 on pmel-1 cells and initial pmel-1 dose.858 T CELL PRECURSOR FREQUENCY AND TUMOR IMMUNITY | Rizzuto et al.
generation of populations capable of performing multiple ef-
fector functions (36). Thus, the ability of the pmel-1 effector 
cells located at the tumor, DLNs, and spleen to secrete effec-
tor cytokines and to degranulate was investigated. 4 d after 
B16-matrigel tumor implantation, dose groups were treated 
and prepared as described in Fig. 3 A, and organs were har-
vested 5 d after one vaccination with hgp100. Flow cytome-
try was used to determine IFN- and TNF- production 
and  to  assess  degranulation  by  staining  for  CD107a.  We 
adopted a definition of polyfunctionality as the ability to per-
form any two of these functions.
Cytokine profiles for gated CD8+Thy1.1+ pmel-1 cells 
from tumor and DLN are shown in Fig. 6 A. Effectors gener-
ated from 103 and 105 pmel-1 precursors secreted more IFN- 
and more TNF- on a population level than those generated 
of  activated  pmel-1  cells  after  transfer  into  nonirradiated 
mice (unpublished data).
These  results  suggest  that  the  impaired  proliferative 
burst and acquisition of effector phenotype at the high doses 
are the result of early competition between the pmel-1 
transgenic clones. This outcome is consistent with reports 
of intraclonal competition for foreign antigens (31). This 
led us to test whether intraclonal competition at the higher 
pmel-1 input number impaired the gain of antitumor effec-
tor function.
Polyfunctional CD8+ self-antigen–specific effector cells are 
generated at low, but not high, initial precursor frequencies
It has been suggested that the high-quality protection elicited 
by successful CD8+ T cell vaccines can be correlated with the 
Figure 6.  Polyfunctional antigen-specific effector CD8+ cells are generated at lower, but not higher, precursor frequencies. (A) Mice (n = 4–6/
group) were inoculated subcutaneously with B16-matrigel tumors, and underwent sublethal irradiation and adoptive transfer 4 d later and vaccination 
with hgp100-encoding plasmid the following day. 5 d after vaccination, tumors, DLNs, and spleens were harvested. Cells were stimulated for 6 h with EL4 
cells and either mgp10025-33 or irrelevant peptide, and then stained for cytokine production (TNF- and IFN-) and CD107a mobilization. TNF- and IFN- 
production by gated CD8+Thy1.1+ pmel-1 cells is shown for pooled tumors and pooled DLNs. (B) Cytokine+ and CD107a+ cells from A were subject to 
Boolean gate analysis, and functionality profiles are shown as pie graphs. (C) Graph showing the mean fluorescence intensity (MFI) of IFN- for IFN-
+CD8+Thy1.1+ pmel-1 cells from individual spleens stimulated with mgp10025-33. P < 0.001 for an overall inverse association between MFI of IFN- and 
initial pmel-1 dose. Shown is one representative experiment out of three experiments (CD107a, IFN-) and two experiments (CD107a, IFN-, and TNF-).JEM VOL. 206, April 13, 2009 
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Distinct “memory” phenotypes are generated from different 
initial self-antigen–specific precursor frequencies
As antigen is cleared during the resolving effector response, 
the typical fate of T cell populations is contraction, leaving 
behind  a  much  smaller  population  of  central  and  effector 
memory cells. On the other hand, the process of memory dif-
ferentiation  in  the  presence  of  antigen  is  characterized  by 
stages of exhaustion and/or deletion (38). Recent reports have 
demonstrated a role for precursor frequency in the generation, 
subset diversification, and survival of memory cells for foreign 
antigens (39–41). Therefore, we were interested in determin-
ing the phenotypic and functional fate of the pmel-1 memory 
populations in our treated mice. Indeed, the development of 
coat depigmentation in our treated mice suggests continued 
recognition of gp100 self-antigen (Fig. 2, D and E), although 
it is possible that loss of melanocytes may be a direct conse-
quence of epitope spreading to other melanocyte-specific an-
tigens, and not gp10025-33 recognition-dependent killing.
We phenotyped the pmel-1 populations present at day 85 
after vaccination in mice that had survived tumor challenge 
(Fig. 7 A). Spleens of individual animals were analyzed by flow 
cytometry, and as was observed during the effector response, 
the phenotype of the pmel-1 populations looked strikingly dif-
ferent. Pmel-1 CD44hiCD62Llo cells predominated in memory 
populations generated from low input numbers (Fig. 7 B). One 
might speculate that the activated effector phenotype acquired 
by the great majority of pmel-1 cells at the 103 dose is main-
tained  because  of  continued  encounter  with  self-antigen. 
Therefore, we assessed for functional exhaustion, but did not 
observe an overt loss of cytokine-secreting abilities in cells har-
vested and briefly restimulated in vitro at 72 d after vaccination 
(Fig. 7 C; compare with effector responses shown in Fig. 6 A).
These data indicate that precursor frequency is an impor-
tant dictator of memory phenotype and function for CD8+ T 
cells recognizing a self-antigen.
DISCUSSION
Successful  immunotherapy  of  established,  poorly  immuno-
genic melanoma tumors has been accomplished in only a few 
ways  (30,  42).  In  particular,  treatment  regimens  using  the 
adoptive transfer of tumor-specific CD8+ T cells have achieved 
durable cures (43–45). The quality and quantity of adoptively 
transferred cells are important parameters when optimizing 
such a treatment. Many studies to date have focused on aspects 
of in vitro generation, activation, and expansion of tumor-spe-
cific cells for transfer (46–49). Unfortunately, prolonged in vi-
tro  culture  correlates  with  impaired  in  vivo  function  after 
transfer (50). Indeed, an in vitro priming and expansion model 
that completely mimics optimal in vivo effector and memory 
generation remains elusive. Thus, we chose to explore the 
transfer of naive, tumor-antigen–specific CD8+ cells that 
would then be activated in the mouse. We used in vivo ad-
ministration of an altered-self vaccine to activate our trans-
ferred cells at lymph nodes draining the site of disease, as tissue 
tropism is known to be imparted to T cells during in situ prim-
ing (51). Future work comparing the trafficking, persistence, 
from the higher precursor frequencies. The same trend held 
true, though less strikingly, for CD107a mobilization (Fig. 
S2,  available  at  http://www.jem.org/cgi/content/full/jem 
.20081382/DC1).  We  analyzed  the  ability  of  the  pmel-1 
populations from pooled DLN and tumor to perform one, 
two, or all three of these functions (Fig. 6 B; mean values ± 
SD for individual spleens are shown in Fig. S3). In all organs, 
the effector populations generated from the two lower pre-
cursor  frequencies  were  more  highly  polyfunctional  than 
were populations generated at higher precursor frequencies. 
Notably, however, the absolute number of polyfunctional   
effectors was comparable and/or higher at the increased 
pmel-1 doses (Fig. S4).
These same trends were observed for animals that received 
vaccination with the self-homologue mouse gp100 (unpub-
lished data). Although the mouse homologue was detectably 
immunogenic under these conditions, the magnitude of the 
response, in comparison to that generated with hgp100 vacci-
nation, was lower. We also performed a side-by-side compari-
son of polyfunctional T cell responses generated from pmel-1 
cells transferred into irradiated and naive (nonirradiated) recip-
ients (unpublished data). Similar, although less striking, trends 
were observed with the exception that in the naive recipient 
the frequency of CD107a+TNF-+IFN-+ cells was highest 
in the 106 dose group.
Three observations are noteworthy, as they may be di-
rectly related to the increased treatment efficacy at lower pre-
cursor frequencies. First, after restimulation with irrelevant 
peptide, a population of IFN-+ pmel-1 cells are detected in 
the tumors of animals receiving lower numbers of pmel-1 
cells (Fig. 6 A). Similar levels of IFN-+ pmel-1 cells are de-
tected in wells that received no peptide at all (not depicted), 
suggesting that effector cells generated from lower precursor 
frequencies are truly functional directly ex vivo. Second, the 
higher pmel-1 dose groups yielded a greater frequency of ef-
fector pmel-1 cells in the DLN that produced only TNF- 
(Fig. 6 B). Similarly, a greater frequency of pmel-1 effectors 
that  produced  only  TNF-  was  generated  by  vaccination 
with mouse gp100 (unpublished data). The significance of 
this population is not currently known. Perhaps these cells 
represent a population that under lower levels of intraclonal 
competition would also acquire the ability to secrete IFN- 
and/or degranulate. Third, the mean fluorescence intensity of 
IFN- is consistently higher in pmel-1 populations activated 
at lower precursor frequencies (Fig. 6 C), suggesting the abil-
ity to secrete more cytokine. Interestingly, our data suggests 
that CD107a+TNF-+IFN-+ pmel-1 effectors are cells with 
higher intensity staining for IFN- (Fig. S5, available at http://
www.jem.org/cgi/content/full/jem.20081382/DC1). Perhaps 
the most polyfunctional cells secrete the most cytokine. This 
observation is consistent with increased MFI of IFN- ob-
served for Leishmania-specific CD4+ cells in mice (37) and 
human CD8+ cells against modified vaccinia virus (36).
Therefore, precursor frequency dictates several qualita-
tive aspects of the effector response that are known to be im-
portant for tumor eradication.860 T CELL PRECURSOR FREQUENCY AND TUMOR IMMUNITY | Rizzuto et al.
and efficacy of in vitro–activated versus in vivo–primed tu-
mor-specific cells is warranted.
The initial precursor frequency of foreign antigen–specific 
T cells in the mouse is low, with reported estimates ranging 
from 10 to 3,000 cells/mouse (20–26). During the natural im-
mune response to foreign pathogens, these antigen-specific 
cells expand and, if allowed to subsequently contract as anti-
gen is cleared, will form long-lived memory (52). The resul-
tant effector and memory T cell populations look and behave 
dramatically different depending on precursor frequency (31, 
39–41, 53). Studies addressing the mechanism of this phe-
nomenon illustrate that intraclonal competition for foreign 
antigens occurs at the level of the APC where clones of the 
same specificity compete for peptide–MHC complexes (39, 
54, 55). Our results demonstrate that the same phenomenon 
holds true for T cell clones that recognize a tissue-restricted 
self-antigen. We show that the proliferative burst is stunted at 
high initial frequencies, as is the acquisition of effector pheno-
type. We extend published findings to report that precursor 
frequency dictates acquisition of polyfunctional effector CD8+ 
T cells. Priming at low precursor frequency generated a greater 
frequency  of  IFN-+TNF-+CD107a+  cells,  which  were 
present at both the tumor site and draining lymph node.
Most significantly, eradication of B16 melanoma tumors is 
impaired at high initial frequencies. Our data suggest that this 
is the negative consequence of priming T cells at supraphysi-
ological precursor frequencies and we believe this is clinically 
relevant information. We predict the same negative conse-
quences in models where mice are challenged with foreign 
pathogens. Thus, clinical protocols designed to activate adop-
tively transferred CD8+ T cells should consider these effects.
Several published reports address the frequency of the   
human T cells specific for the melanoma differentiation anti-
gen Melan-A/MART-1 restricted to HLA-A*0201, and the 
melanoma cancer testes antigen MAGE-3168-176 presented on 
HLA-A1. Using tetramer staining, Pittet et al. described a 
surprisingly high frequency (1 in 2,500 CD8+ T cells) of 
Melan-A/MARTI-1–specific T cells in some, but not all, 
healthy, HLA-A*0201+ individuals (56). Later, it was shown 
that the majority of this population was not functionally reac-
tive to Melan-A/MART-1, but rather to similar peptide ana-
logues (57). It is unclear how commonly this phenomenon 
occurs in the T cell repertoire against self. The frequency   
of anti–MAGE-3–specific CD8+ T cells in an individual 
without cancer was estimated to be much lower, 6 × 107, 
with a repertoire consisting of an estimated >100 different   
Figure 7.  Precursor frequency impacts phenotype of CD8+ “mem-
ory” populations. Phenotype of pmel-1 CD8+ cells was analyzed by flow 
cytometry 6 wk after last vaccination. (A) Surviving animals from tumor 
treatment experiment shown were killed 85 d after the last vaccination. 
(B) Individual spleens were harvested, stained, and analyzed by flow cy-
tometry for CD44 and CD62L expression on CD8+Thy1.1+ pmel-1 cells. Dot 
plots and histograms are shown for representative spleens, and individual 
values are plotted on graphs. P < 0.001 for an inverse overall association 
between the percentage of CD44hiCD62Llo and initial pmel-1 dose.  
(C) Naive mice (n = 2–3/group) underwent irradiation and adoptive trans-
fer with 105 or 6 × 106 pmel-1 cells, received three weekly vaccinations, 
and were rested for 72 d. DLNs were harvested and cells were stimulated 
for 6 h with EL4 cells and either mgp10025-33 or irrelevant peptide and 
stained for cytokine production. TNF- and IFN- staining by gated 
CD8+Thy1.1+ pmel-1 cells are shown for representative mice. Data are 
from at least two independent experiments that were performed under 
similar conditions.
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nous clones (unpublished data). Thus, we must consider that 
low precursor frequency and/or low TCR avidity may ex-
plain the impairment in B16 melanoma eradication in ani-
mals that do not receive pmel-1 cells.
It was recently demonstrated that even a single cell can 
give rise to multiple effector and memory lineages, perhaps 
by asymmetrical cell division (61, 62). However, our results 
suggest that a sizeable proliferative burst is needed to destroy 
a progressively growing malignancy. Indeed, populations of 
greater initial size might simply have a kinetic advantage. 
This concept is modeled in Fig. 8. We propose that the opti-
mal precursor frequency for generating high-quality antitu-
mor  CD8+  responses  can  be  reached  by  using  adoptive 
transfer to supplement the naive repertoire. However, when 
clonal frequency rises above a certain threshold, competition 
diminishes the quality of the antitumor immune response.
This model (Fig. 8) raises many questions. How similar is 
this dose-response curve for CD8+ T cells recognizing for-
eign antigens? For CD8+ T cells recognizing other self-anti-
gens? For CD8+ T cells primed in the nonirradiated host? 
Although preliminary data suggest that intraclonal pmel-1 
cell competition is operative in the nonirradiated animal, 
clonotypes (58). Anti–MAGE-3 vaccine induced detectable 
CD8+ T cell responses in some patients, and most of these 
responses were monoclonal (59, 60). Interestingly, we also 
observed  a  very  restricted  vaccine-induced  anti-gp10025-33 
response in mice that was limited to between 1 and 4 re-
sponding TCR V per mouse.
Our estimate of endogenous gp10025-33 clonal frequency 
is, to our knowledge, the lowest reported for any mouse an-
tigen. To estimate precursor frequency, we adopted a method 
of indirect determination initially reported by Blattman et al. 
(23). We recognize that this method assumes that preimmune 
transgenic cells and endogenous antigen-specific precursors 
have similar propensities to enter the response, undergo simi-
lar priming, and possess similar expansion and differentiation 
capabilities. Unfortunately, we cannot rule out the possibility 
that endogenous clones may respond to antigen in a qualita-
tively and quantitatively different manner than pmel-1 cells. 
We  tested  and  compared  recognition  of  mgp10025-33  by 
pmel-1 cells and endogenous responders, by analyzing fre-
quency of IFN- cells relative to titrating peptide. Using this 
surrogate measure of affinity, we found that the pmel-1 clone 
is of higher avidity than at least six (of seven tested) endoge-
Figure 8.  A model for the impact of antigen-specific precursor frequency on the quality of antitumor responses. (A) The mean values for pa-
rameters shown were calculated for experimentally tested pmel-1 dose groups (0, 103, 105, 106, and 6 × 106). For each parameter, the maximal response 
was set at 100%, and responses for other pmel-1 dose groups were calculated as a percentage of this maximum. Values from spleen, DLN, and tumor are 
shown graphically. (B) Model based on A. The x axis shows the number of naive tumor antigen–specific CD8+ T cells present at the time of vaccine admin-
istration. The y axis is the quality of the antitumor immune response. The curve demonstrates that there is an optimal precursor frequency for generating 
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individual function? Future studies should address whether 
these cells actually do produce more of each individual cyto-
kine and whether this cytokine is responsible for antitumor 
and viral outcomes.
It is both puzzling and intriguing that the absolute num-
ber of activated (CD44hiCD62Llo) effectors with the ability 
to secrete cytokines or degranulate is not greater at the lower 
precursor frequencies, despite the improved efficacy of these 
frequencies (Fig. S4 and not depicted). The decreased tumor 
growth observed in these animals may be correlated with an 
as yet undefined effector capability. For example, these effec-
tors may be better at penetrating the tumor mass, or they may 
be less susceptible to suppression by regulatory T or myeloid 
cells at the tumor site. Another attractive hypothesis is that 
effectors generated from the lower doses are of higher func-
tional avidity, such that they are better capable of recognizing 
B16 melanoma tumors that presumably express low levels of 
MHC–gp10025-33 peptide complexes. Others have hypothe-
sized that only a small number of effectors might be capable 
of initiating tumor rejection, which is performed by the ac-
tive recruitment of other immune effector cells (60). Perhaps 
we might detect significant numbers of CD8+ and/or CD4+ 
T cells specific for other melanoma antigens in animals that 
receive lower precursor frequency pmel-1 cells and subse-
quently reject tumor. This is currently under investigation.
Alternatively, the presence of large numbers of unacti-
vated pmel-1 cells at the higher doses may directly or indi-
rectly inhibit the response of those few activated effectors. 
Recent reports have identified and characterized a popula-
tion of IL-10–secreting, CD8+ suppressor cells in naive mice 
(68, 69). These cells are distinguished by high levels of CD122 
(IL-2/-15R). Notably, we detected high levels of CD122 
on pmel-1 “memory” populations generated from high pre-
cursor frequencies in vaccinated animals (not depicted). In 
contrast, CD122 expression on memory pmel-1 populations 
generated from lower precursor frequencies (103 or 105 pmel-
1 cells) ranged from uniformly low to negative. Notably, the 
memory population in animals receiving 105 pmel-1 cells, 
but no vaccination, also displayed high levels of CD122. Per-
haps weak self-reactivity, as is expected for homeostatically 
expanded but nonvaccinated pmel-1 cells, leads to CD122 
up-regulation. Whether these cells have functional properties 
similar to published CD8+CD122+ suppressors remains to be 
established, and ongoing experiments are aimed at testing this 
hypothesis as well.
Promising clinical trials have tested infusion of autologous 
T cells into lymphoablated patients, in some cases combined 
with vaccination (70–74). Sources of tumor-reactive T cells 
have  included  autologous  tumor  infiltrating  lymphocytes, 
autologous PBL cells, and vaccine-primed autologous T cells 
from blood or DLNs (43, 45). Current strategies using adop-
tive immunotherapy in the clinical setting of cancer are based 
on the premise that “more” is better with great effort spent in 
the generation of tens of billions of antitumor T cells for 
transfer. To our knowledge, all reports involved ex vivo ma-
nipulation to activate and/or expand the tumor-reactive T 
there appears to be an approximate 1-log difference in the 
effect when compared with irradiated animals (unpublished 
data). Further study will be aimed at exploring the detailed 
differences observed in the naive versus irradiated recipient.
Notably, in one study, at high precursor frequencies, more 
CD4+ T cells were shown to enter the response simply by pro-
viding more antigen (63). Conversely, limiting the effective 
antigen dose by addition of monoclonal antibody specific for a 
particular MHC–peptide complex impaired the differentiation 
of peptide-specific memory cells (39). Thus, there seems to be 
built-in regulation of the size of the immune response depend-
ing on the “size” of the antigenic insult. It is predicted that in-
creasing antigen dose would raise the threshold where pmel-1 
intraclonal competition becomes operative, whereas decreasing 
antigen would lower it. However, the possibility that increas-
ing antigen dose may limit the efficacy of vaccine-generated 
antitumor immunity must also be considered. Greater antigen 
availability may allow for recruitment of increased numbers of 
endogenous, and for lower affinity clones, leading to a com-
parative decrease in tumor killing.
It is likely that at all stages of an immune response, reactive 
lymphocytes require many resources that are naturally limiting. 
These resources include antigen, but might also include co-
stimulation, cytokines, other survival signals, and CD4 help 
(64). We hypothesize that the absence/presence and levels of 
these other variables modulate the curve presented in Fig. 8. 
Current and future work will address the relevance of these, 
most of which are easily delivered by plasmid and gene gun (9, 
65). Lastly, it is well documented that under certain conditions, 
the TCR repertoire is less diverse (19). During aging, HIV in-
fection, or in the posttransplant setting, reactivity to gp10025-33 
might be lost because of deficiencies in the repertoire.
It is intriguing that precursor frequency dictates polyfunc-
tionality of the pmel-1 effector T cell response generated by 
vaccination in our model. Recent advances in multiparame-
ter flow cytometry have enabled the study of both the phe-
notype and function of human CD8+ T cells in the setting of 
chronic viral infection; with and without the addition of ex-
perimental vaccines. However, the correlates of protection 
for CD8+ T cell mediated vaccination against either chronic 
infection, such as HIV or tumors, are not yet clearly defined 
(66). Current experts argue that it is not enough to simply 
monitor the magnitude of vaccine-induced CD8+ T cell re-
sponse, such as the frequency of IFN-+ cells by ELISPOT 
(67). To understand the best CD8+ T cell correlates of tumor 
protection, we must understand the T cell response in its en-
tirety—that is the patterns of production of multiple cyto-
kines and chemokines. We believe that further exploration 
into the effector response generated in our model may be 
useful in defining CD8+ T cell correlates of antitumor pro-
tection. Whether polyfunctional cells actually cause disease 
regression or are simply a consequence thereof will require 
the study of mouse and nonhuman primate models, where 
outcomes and responses can be easily manipulated. For ex-
ample, are polyfunctional CD8+ T cells better just because of 
their increased functions or because they are superior at an JEM VOL. 206, April 13, 2009 
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Plasmid constructs and DNA immunization. The WRG/BEN vector 
construct containing hgp100 was used for immunizing against mgp100 (10, 
12). The same vector backbone containing mgp100 was used in some ex-
periments. An ovalbumin–minigene construct, described previously (12), 
was used for priming SIINFEKL-specific responses. Vaccine was prepared 
by coating 1.5-µM gold particles (Alfa Aesar) with purified DNA, and pre-
cipitated onto bullets of Teflon tubing (1 µg plasmid/bullet). A high-pres-
sure, helium-driven gene gun (Accell; PowderMed) was used for cutaneous 
particle bombardment of DNA into mouse skin. In brief, mouse hair was re-
moved by depilation, and one bullet was delivered to each abdominal quad-
rant for a total of 4 µg plasmid/mouse (9).
TCR V determination. One-third of total spleen and lymph nodes cells 
from individual mice with positive responses to vaccine were stained with 
hgp100-tetramer and FITC-conjugated antibodies specific for TCR- fami-
lies (Mouse V TCR Screening Panel; BD). Remaining cells from these 
same mice were enriched for CD8+ with EasySep Mouse CD8+ T Cell En-
richment kits and one round of negative selection through an EasySep Mag-
net (Stem Cell Technologies). Samples were FACS sorted to yield 99% 
pure hgp100-tetramer+CD8+ populations and total RNA was extracted with 
an RNeasy Micro kit (QIAGEN). Each sample was reverse transcribed with 
a High Capacity cDNA Archive kit (Applied Biosystems). PCR amplifica-
tion  of  CDR3  regions  was  performed  with  family-specific  V  forward 
primers and a TCR- constant region-specific reverse primer designed by P. 
Savage (78). Reactions were performed with annealing at 55°C, for 20–40 
cycles. PCR products were cloned into pCR4-TOPO vector with TOPO 
TA  Cloning  kit  for  sequencing  (Invitrogen)  and  sequenced  by  standard 
methods. TCR J and CDR3 regions were classified and reported using the 
International ImMunoGeneTics Information System nomenclature (79).
Isolation of lymphocytes from tumors. Subcutaneous B16-Matrigel 
tumors were inoculated as described in Materials and methods and removed 
by dissection at various time points after treatment. Tumor tissue was di-
gested with 2 mg/ml Collagenase D (Roche) and 1 mg/ml DNase I (Sigma-
Aldrich) for 1 h at 37 degrees, passed through 40-µM filters, and mononuclear 
cells were isolated by density gradient centrifugation. In brief, cell pellets 
were resuspended in 80% Percoll (GE Healthcare), overlaid with 40%, and 
the interface was isolated after 30 min of room temperature centrifugation. 
Cells were washed twice, and if necessary, RBC lysis was performed with 
ammonium chloride lysis buffer (1.5 M NH4Cl, 10 mM EDTA disodium 
salt, and 100 mM NaHCO3).
Flow cytometry. The following fluorochrome-conjugated antibodies were 
purchased from BD: anti-V13 (MR12-3), V5.1/5.2 (MR9-4), CD3e (145-
2C11), CD62L (MEL-14), CD4 (RM4-5), CD8a (53–6.7), Thy1.1 (HIS51 and 
OX-7),  Thy1.2  (53–2.1),  CD107a  (1D4B),  TNF-  (MP6-XT22),  IFN- 
(XMG1.2), CD122 (TM-1), CD19 (1D3), and Ki67 (B56).
Other  antibodies  were  purchased  from  eBioscience:  CD44  (IM7), 
CD62L (MEL-14), and LFA-1 (M17/4). Anti-mouse CD8a (5H10) was 
purchased from Invitrogen.
Surface staining using antibody quantities predetermined by titration ex-
periments was performed in a total volume of 100 µl PBS containing 1% BSA 
on ice for 20–30 min in the dark. Cells were washed twice before and after 
staining. All surface stains were performed following blockade of FCIII/II 
receptor with purified, unlabeled antibody (clone 2.4G2; BD). Before acquisi-
tion, cells were resuspended in DAPI (Invitrogen) to permit dead cell exclu-
sion. Samples were acquired and electronically compensated on a LSR II 
(BD), and exported for analysis in FlowJo (Tree Star, Inc.).
In some cases, gp100-reactive CD8+ cells were identified by staining with 
PE-conjugated tetramer containing the Db epitope from hgp100, KVPRN-
QDWL (12) purchased from Beckman Coulter. Hgp10025-33 peptide was used 
for production rather than self-mouse peptide because only the higher affinity 
peptides were able to form tetramers. Cells were washed and stained at room 
temperature in PBS containing 1% BSA and anti-CD8 clone 53–6.7 was always 
chosen for use when staining for tetramer. In some experiments, a channel for 
cells. Our results show that combining lymphodepletion with 
physiologically  relevant  numbers  of  naive  tumor-specific 
CD8+ cells and in vivo administration of an effective vaccine 
generates a high-quality, antitumor response in mice. This 
approach requires strikingly low numbers of naive tumor-spe-
cific cells, making it a new and truly potent treatment strat-
egy. Emerging technologies, notably lentiviral gene transfer, 
make it possible to genetically arm T cells with tumor speci-
ficity without the need for overt activation (75). We recom-
mend that future trials combining adoptive immunotherapy 
and vaccination explore an in vivo activation strategy such as 
the one we present here. Care should be taken when formu-
lating the dose of transferred cells, which, when modulated, 
may turn an ineffective treatment into one which results in 
robust tumor control.
MATERIALS AND METHODS
Mice and tumors. Mouse work was performed in accordance with institu-
tional guidelines under a protocol approved by Memorial Sloan-Kettering 
Cancer Center Institutional Animal Care and Use Committee. All mice 
were maintained in a pathogen-free facility according to National Institutes 
of Health Animal Care guidelines. C57BL/6J mice (females, 6–10 wk old) 
were purchased from The Jackson Laboratory. Pmel-1 TCR transgenic mice 
have been reported (30) and were bred with Thy1.1+ C57BL/6J mice (76) 
(The Jackson Laboratory) as a source of tumor-specific CD8+ T cells. For 
some experiments, Thy1.1+/Thy1.2+ Pmel-1 TCR transgenic mice were 
generated and used as a source of otherwise identical tumor-specific CD8+ 
T cells.
The mouse melanoma cell line B16F10 (hereafter referred to as “B16”) was 
originally obtained from I. Fidler (M.D. Anderson Cancer Center, Houston, 
TX).  Cells  were  cultured  as  previously  described  (77).  For  experiments 
where rejection and growth of tumors were monitored, 105 (or 1.25 × 105  
for some experiments) live cells were intradermally injected in the shaved 
flank of mice. Tumor growth was monitored by inspection with calipers 3–4 
times/wk, and mice were killed when tumors ulcerated and/or reached   
1 cm in diameter.
B16 cells mixed with Matrigel Basement Membrane Matrix, Growth 
Factor Reduced (BD) were subcutaneously inoculated in the shaved flank of 
mice for experiments where tumors were later harvested for analysis of tu-
mor-infiltrating immune cells.
To assess coat depigmentation in mice that rejected tumor, animals were 
anaesthetized and abdomens were scanned with a Hewlett-Packard Series 
650 scanner and HP PrecisionScanPro software. Resolution for all images 
was lowered to accommodate images of individual mice <100 MB in size. 
Average pixels were quantified with UN-SCAN-IT gel software, version 
4.3 (Silk Scientific, Inc.). In brief, four similarly sized quadrants were sub-
jected to segment analysis for each animal and the mean number of pixels per 
segment area was calculated.
Irradiation and adoptive transfer. Recipient mice received 600 cGy to-
tal body irradiation from a 137Cs source several hours before adoptive trans-
fer. Transgenic pmel-1 donor mice were 6–12-wk-old females that had yet 
to begin showing signs of coat depigmentation. CD8+ T cells were purified 
from spleen and subcutaneous lymph nodes using EasySep Mouse CD8+ T 
Cell Enrichment kits, according to the manufacturer’s suggested protocol 
with two rounds of negative selection through an EasySep Magnet (Stem-
Cell Technologies). CD8+ purity was assessed by flow cytometry and was 
typically between 87–95%. For adoptive transfer, dose groups were washed 
twice with PBS, resuspended at 30 million cells per 200 µl, and injected via 
lateral vein into irradiated recipient animals. Dose groups were confirmed   
by flow cytometry, as was the naive phenotype of pmel-1 donors with   
CD44loCD62Lhi percentages similar to naive, wild-type CD8+ T cells.864 T CELL PRECURSOR FREQUENCY AND TUMOR IMMUNITY | Rizzuto et al.
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CD4+ and CD19+ cells was used to exclude background staining and enhance 
detection of low-frequency Tetramer+CD8+ cells.
Intracellular cytokine and CD107a mobilization assay. Cells were 
stimulated with 1 µg/ml peptide in the presence of EL-4 cells, at a ratio of 
10 or 20:1, in complete RPMI 1640 medium containing 7.5% FBS. For si-
multaneous detection of CD107a and TNF-, both Brefeldin A (BFA) and 
monesin secretion inhibitors were added to the culture after one hour incu-
bation (80). After 6 h of incubation, samples were stained for surface mark-
ers. Cells were then fixed and permeabilized using Cytofix/Cytoperm kit 
(BD) according to the manufacturer’s instructions, stained for intracellular 
TNF- and IFN-, and analyzed on a LSR II flow cytometer (BD).
To determine whether antigen-specific CD8+ pmel-1 cells were capable 
of one, two, or three functions (CD107a mobilization, and/or secretion of 
either TNF- and IFN-). Boolean Gate analysis was performed in FlowJo 
(Tree Star, Inc.).
Statistical calculations. Six treatment strategies were assessed comprising 
five treatment group (pmel-1 doses) and one control group (naive). Because 
of the small sample sizes, comparisons between treatment strategies were as-
sessed using the Mann-Whitney U (two groups) or Kruskal-Wallis (more than 
two groups) tests. Because of the exploratory nature of these analyses, results 
were not adjusted for multiple comparisons, unless otherwise indicated. Tu-
mor-free survival curves were estimated using the Kaplan-Meier method 
and comparisons between groups were made using the Mann-Whitney U 
test because all mice were followed to the study end date.
Online supplemental material. Fig. S1 shows flow cytometric contour plots 
for individual vaccinated animals (receiving either 0 or 10 pmel-1 cells) that were 
used to estimate endogenous gp10025-33–reactive CD8+ T cell precursor fre-
quency. In Fig. S2, tumor and DLN pmel-1 cell CD107a mobilization for differ-
ent starting precursor frequencies is shown. Fig. S3 depicts polyfunctionality 
profiles for splenic pmel-1 cells, while Fig. S4 shows the absolute number of these 
same sub-groups. Overlaid staining intensity for IFN- produced by mono- and 
polyfunctional pmel-1 sub-groups is shown in Fig. S5. Online supplemental ma-
terial is available at http://www.jem.org/cgi/content/full/jem.20081382/DC1. 
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